Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes

Journal of Bone and Mineral Research

Volumn 28, Issue 1, 2013, Pages 46-55

  Bacchetta, Justine ^a,b   Sea, Jessica L ^a   Chun, Rene F ^a   Lisse, Thomas S ^a   Wesseling Perry, Katherine ^b   Gales, Barbara ^b   Adams, John S ^a   Salusky, Isidro B ^b   Hewison, Martin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FGF23; INNATE IMMUNITY; MONOCYTES; PERITONEAL DIALYSIS; VITAMIN D

Indexed keywords

CALCITRIOL; CATHELICIDIN; FIBROBLAST GROWTH FACTOR 23; INTERLEUKIN 15; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; OXYGENASE; PROTEIN KINASE B; STEROID 24 HYDROXYLASE; UNCLASSIFIED DRUG;

ARTICLE; CELL ISOLATION; CELL TYPE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; KIDNEY DISEASE; MONOCYTE; PERITONEAL DIALYSATE MONOCYTE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; CELL SEPARATION; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; GLUCURONIDASE; HUMANS; KIDNEY; MONOCYTES; PERITONEAL DIALYSIS; RECEPTORS, FIBROBLAST GROWTH FACTOR; RNA, MESSENGER; SIGNAL TRANSDUCTION; VITAMIN D;

EID: 84872841888     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1740     Document Type: Article

References (64)

1. Liu S, Quarles LD,. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007; 18 (6): 1637-47.
2. Yamazaki Y, Tamada T, Kasai N, Urakawa I, Aono Y, Hasegawa H, Fujita T, Kuroki R, Yamashita T, Fukumoto S, Shimada T,. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res. 2008; 23 (9): 1509-18.
3. Yoshiko Y, Wang H, Minamizaki T, Ijuin C, Yamamoto R, Suemune S, Kozai K, Tanne K, Aubin JE, Maeda N,. Mineralized tissue cells are a principal source of FGF23. Bone. 2007; 40 (6): 1565-73.
4. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T,. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19 (3): 429-35.
5. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T,. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004; 113 (4): 561-8.
6. Razzaque MS, Sitara D, Taguchi T, St-Arnaud R, Lanske B,. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. The FASEB J. 2006; 20 (6): 720-2.
7. Sitara D, Razzaque MS, St-Arnaud R, Huang W, Taguchi T, Erben RG, Lanske B,. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol. 2006; 169 (6): 2161-70.
8. Hewison M, Vitamin D,. Vitamin D and innate and adaptive immunity. Vitam Horm. 2011; 86: 23-62.
9. Adams JS, Hewison M,. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab. 2008; 4 (2): 80-90.
10. Gombart AF, Borregaard N, Koeffler HP,. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005; 19 (9): 1067-77.
11. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, Tavera-Mendoza L, Lin R, Hanrahan JW, Mader S, White JH,. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004; 173 (5): 2909-12.
12. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL,. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006; 311 (5768): 1770-3.
13. Adams JS, Ren S, Liu PT, Chun RF, Lagishetty V, Gombart AF, Borregaard N, Modlin RL, Hewison M,. Vitamin d-directed rheostatic regulation of monocyte antibacterial responses. J Immunol. 2009; 182 (7): 4289-95.
14. Krutzik SR, Hewison M, Liu PT, Robles JA, Stenger S, Adams JS, Modlin RL,. IL-15 links TLR2/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. J Immunol. 2008; 181 (10): 7115-20.
15. Edfeldt K, Liu PT, Chun R, Fabri M, Schenk M, Wheelwright M, Keegan C, Krutzik SR, Adams JS, Hewison M, Modlin RL,. T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. Proc Natl Acad Sci U S A. 2010; 107 (52): 22593-8.
16. Consortium A,. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000; 26 (3): 345-8.
17. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H,. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003; 348 (17): 1656-63.
18. Danziger J,. The bone-renal axis in early chronic kidney disease: an emerging paradigm. Nephrol Dial Transplant. 2008; 23 (9): 2733-7.
19. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M,. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011; 79 (12): 1370-8.
20. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P,. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007; 18 (9): 2600-8.
21. Kazama JJ, Gejyo F, Shigematsu T, Fukagawa M,. Role of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism. Ther Apher Dial. 2005; 9 (4): 328-30.
22. Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M,. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int. 2005; 67 (3): 1171-8.
23. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M,. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359 (6): 584-92.
24. Mirza MA, Hansen T, Johansson L, Ahlstrom H, Larsson A, Lind L, Larsson TE,. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant. 2009; 24 (10): 3125-31.
25. Mirza MA, Larsson A, Lind L, Larsson TE,. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009; 205 (2): 385-90.
26. Parasuraman R, Samarapungavan D, Venkat KK,. Updated principles and clinical caveats in the management of infection in renal transplant recipients. Transplant Rev (Orlando). 2010; 24 (2): 43-51.
27. Cohen G, Haag-Weber M, Horl WH,. Immune dysfunction in uremia. Kidney Int Suppl. 1997; 62: S79-82.
28. Sarnak MJ, Jaber BL,. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 2000; 58 (4): 1758-64.
29. Collins AJ, Foley RN, Gilbertson DT, Chen SC,. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol. 2009; 4 (Suppl 1): S5-11.
30. Sardenberg C, Suassuna P, Andreoli MC, Watanabe R, Dalboni MA, Manfredi SR, dos Santos OP, Kallas EG, Draibe SA, Cendoroglo M,. Effects of uraemia and dialysis modality on polymorphonuclear cell apoptosis and function. Nephrol Dial Transplant. 2006; 21 (1): 160-5.
31. Wu S, Ren S, Nguyen L, Adams JS, Hewison M,. Splice variants of the CYP27b1 gene and the regulation of 1,25-dihydroxyvitamin D3 production. Endocrinology. 2007; 148 (7): 3410-8.
32. Hewison M,. Antibacterial effects of vitamin D. Nat Rev Endocrinol. 2011; 7 (6): 337-45.
33. Hewison M, Freeman L, Hughes SV, Evans KN, Bland R, Eliopoulos AG, Kilby MD, Moss PA, Chakraverty R,. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol. 2003; 170 (11): 5382-90.
34. Fritsche J, Mondal K, Ehrnsperger A, Andreesen R, Kreutz M,. Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha,25-dihydroxyvitamin D3 by human dendritic cells. Blood. 2003; 102 (9): 3314-6.
35. Kallas M, Green F, Hewison M, White C, Kline G,. Rare causes of calcitriol-mediated hypercalcemia: a case report and literature review. J Clin Endocrinol Metab. 2010; 95 (7): 3111-7.
36. Sakaki T, Kagawa N, Yamamoto K, Inouye K,. Metabolism of vitamin D3 by cytochromes P450. Front Biosci. 2005; 10: 119-34.
37. Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB, Westin G, Larsson TE,. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007; 195 (1): 125-31.
38. Razzaque MS,. FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player? Am J Physiol Renal Physiol. 2009; 296 (3): F470-6.
39. Juppner H, Wolf M, Salusky IB,. FGF-23: More than a regulator of renal phosphate handling? J Bone Miner Res. 2010; 25 (10): 2091-7.
40. Yang W, Friedman PA, Kumar R, Omdahl JL, May BK, Siu-Caldera ML, Reddy GS, Christakos S,. Expression of 25(OH)D3 24-hydroxylase in distal nephron: coordinate regulation by 1,25(OH)2D3 and cAMP or PTH. Am J Physiol. 1999; 276 (4 Pt 1): E793-805.
41. Zierold C, Mings JA, DeLuca HF,. Regulation of 25-hydroxyvitamin D3-24-hydroxylase mRNA by 1,25-dihydroxyvitamin D3 and parathyroid hormone. J Cell Biochem. 2003; 88 (2): 234-7.
42. Rossini M, Cheunsuchon B, Donnert E, Ma LJ, Thomas JW, Neilson EG, Fogo AB,. Immunolocalization of fibroblast growth factor-1 (FGF-1), its receptor (FGFR-1), and fibroblast-specific protein-1 (FSP-1) in inflammatory renal disease. Kidney Int. 2005; 68 (6): 2621-8.
43. Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K, Wolf M, Salusky IB, Juppner H,. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab. 2010; 95 (2): 578-85.
44. Gattineni J, Twombley K, Goetz R, Mohammadi M, Baum M,. Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. Am J Physiol Renal Physiol. 2011; 301 (2): F371-7.
45. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW, Keane MG, Wolf M,. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011; 121 (11): 4393-408.
46. Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, Xu C, Neubert TA, Zhang F, Linhardt RJ, Yu X, White KE, Inagaki T, Kliewer SA, Yamamoto M, Kurosu H, Ogawa Y, Kuro-o M, Lanske B, Razzaque MS, Mohammadi M,. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol. 2007; 27 (9): 3417-28.
47. Ranch D, Zhang MY, Portale AA, Perwad F,. Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice. J Bone Miner Res. 2011; 26 (8): 1883-90.
48. Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Juppner H, Salusky IB,. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab. 2009; 94 (2): 511-7.
49. Bacchetta J, Dubourg L, Harambat J, Ranchin B, Abou-Jaoude P, Arnaud S, Carlier MC, Richard M, Cochat P,. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab. 2010; 95 (4): 1741-8.
50. Bacchetta J, Salusky IB,. Evaluation of hypophosphatemia: lessons from patients with genetic disorders. Am J Kidney Dis. 2012; 59 (1): 152-9.
51. Kitajima I, Maruyama I, Matsubara H, Osame M, Igata A,. Immune dysfunction in hypophosphatemic vitamin D-resistant rickets: immunoregulatory reaction of 1 alpha(OH) vitamin D3. Clin Immunol Immunopathol. 1989; 53 (1): 24-31.
52. Koeffler HP, Bishop JE, Reichel H, Singer F, Nagler A, Tobler A, Walka M, Norman AW,. Lymphocyte cell lines from vitamin D-dependent rickets type II show functional defects in the 1 alpha,25-dihydroxyvitamin D3 receptor. Mol Cell Endocrinol. 1990; 70 (1): 1-11.
53. Muhe L, Lulseged S, Mason KE, Simoes EA,. Case-control study of the role of nutritional rickets in the risk of developing pneumonia in Ethiopian children. Lancet. 1997; 349 (9068): 1801-4.
54. Souberbielle JC, Body JJ, Lappe JM, Plebani M, Shoenfeld Y, Wang TJ, Bischoff-Ferrari HA, Cavalier E, Ebeling PR, Fardellone P, Gandini S, Gruson D, Guerin AP, Heickendorff L, Hollis BW, Ish-Shalom S, Jean G, von Landenberg P, Largura A, Olsson T, Pierrot-Deseilligny C, Pilz S, Tincani A, Valcour A, Zittermann A,. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev. 2010; 9 (11): 709-15.
55. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y,. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant. 2004; 19 (1): 179-84.
56. Negri AL,. Association of oral calcitriol with improved survival in non-dialysed and dialysed patients with CKD. Nephrol Dial Transplant. 2009; 24 (2): 341-4.
57. Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC, Stewart PM, Hewison M,. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol. 2002; 13 (3): 621-9.
58. Gombart AF, Bhan I, Borregaard N, Tamez H, Camargo CA Jr, Koeffler HP, Thadhani R,. Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis. 2009; 48 (4): 418-24.
59. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C,. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant. 2009; 24 (9): 2792-6.
60. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, Shlipak MG, Whooley MA, Ix JH,. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010; 152 (10): 640-8.
61. Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD,. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol. 2010; 21 (2): 353-61.
62. Hayes ME, O'Donoghue DJ, Ballardie FW, Mawer EB,. Peritonitis induces the synthesis of 1 alpha,25-dihydroxyvitamin D3 in macrophages from CAPD patients. FEBS Lett. 1987; 220 (2): 307-10.
63. Zehnder D, Quinkler M, Eardley KS, Bland R, Lepenies J, Hughes SV, Raymond NT, Howie AJ, Cockwell P, Stewart PM, Hewison M,. Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int. 2008; 74 (10): 1343-53.
64. Wesseling-Perry K, Tsai EW, Ettenger RB, Juppner H, Salusky IB,. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? Nephrol Dial Transplant. 2011; 26 (11): 3779-84.